Evaluation of Complete Pathological Regression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients with BRCA1 Founder Mutation Aided Bayesian A/B Testing Approach

The aim of this study was to evaluate the probability of pathologic complete regression (pCR) by the BRCA1 gene mutation status in patients with triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy. The study involved 143 women (mean age 55.4 ± 13.1 years) with TNBC. The BRCA1...

Full description

Bibliographic Details
Main Authors: Piotr Kedzierawski, Pawel Macek, Izabela Ciepiela, Artur Kowalik, Stanislaw Gozdz
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Diagnostics
Subjects:
Online Access:https://www.mdpi.com/2075-4418/11/7/1144